619 related articles for article (PubMed ID: 33775814)
21. Synergistic effects of ceftazidime/avibactam combined with meropenem in a murine model of infection with KPC-producing Klebsiella pneumoniae.
Zheng M; Li FH; Liu J; Li WJ; Yin RX; Cai DT; Andrey DO; Zheng SL; Gales AC; Zhang WJ; Sun J; Liao XP; Yu Y
J Antimicrob Chemother; 2024 May; 79(5):1069-1080. PubMed ID: 38526879
[TBL] [Abstract][Full Text] [Related]
22. Ceftazidime-Avibactam Resistance Associated with Increased
Coppi M; Di Pilato V; Monaco F; Giani T; Conaldi PG; Rossolini GM
Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 31964792
[TBL] [Abstract][Full Text] [Related]
23. In vitro and in vivo bactericidal activity of ceftazidime-avibactam against Carbapenemase-producing
Zhang W; Guo Y; Li J; Zhang Y; Yang Y; Dong D; Zhu D; He P; Hu F
Antimicrob Resist Infect Control; 2018; 7():142. PubMed ID: 30479755
[TBL] [Abstract][Full Text] [Related]
24. Resistance to Ceftazidime-Avibactam in Klebsiella pneumoniae Due to Porin Mutations and the Increased Expression of KPC-3.
Humphries RM; Hemarajata P
Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28396547
[No Abstract] [Full Text] [Related]
25. KPC-2 allelic variants in
Sanz MB; Pasteran F; de Mendieta JM; Brunetti F; Albornoz E; Rapoport M; Lucero C; Errecalde L; Nuñez MR; Monge R; Pennini M; Power P; Corso A; Gomez SA
Microbiol Spectr; 2024 Mar; 12(3):e0411123. PubMed ID: 38319084
[TBL] [Abstract][Full Text] [Related]
26. Molecular mechanisms responsible KPC-135-mediated resistance to ceftazidime-avibactam in ST11-K47 hypervirulent
Shi Q; Shen S; Tang C; Ding L; Guo Y; Yang Y; Wu S; Han R; Yin D; Hu F
Emerg Microbes Infect; 2024 Dec; 13(1):2361007. PubMed ID: 38801099
[TBL] [Abstract][Full Text] [Related]
27. Increased Expression and Amplification of
Li X; Zhang J; Yang C; Li J; Wang J; Huang W; Zeng L; Liang X; Long W; Zhang X
Microbiol Spectr; 2022 Aug; 10(4):e0095522. PubMed ID: 35900090
[TBL] [Abstract][Full Text] [Related]
28. Increased gene expression and copy number of mutated bla
Sun L; Li H; Wang Q; Liu Y; Cao B
BMC Microbiol; 2021 Aug; 21(1):230. PubMed ID: 34412588
[TBL] [Abstract][Full Text] [Related]
29. Ceftazidime-Avibactam resistance in clinical isolates of carbapenem-resistant Klebsiella pneumoniae: A phenotypic and genotypic analysis.
Krithika VM; Ganesan V; Rajendran T
Indian J Med Microbiol; 2024; 49():100603. PubMed ID: 38705276
[TBL] [Abstract][Full Text] [Related]
30. Reversal of carbapenemase-producing Klebsiella pneumoniae epidemiology from blaKPC- to blaVIM-harbouring isolates in a Greek ICU after introduction of ceftazidime/avibactam.
Papadimitriou-Olivgeris M; Bartzavali C; Lambropoulou A; Solomou A; Tsiata E; Anastassiou ED; Fligou F; Marangos M; Spiliopoulou I; Christofidou M
J Antimicrob Chemother; 2019 Jul; 74(7):2051-2054. PubMed ID: 31002313
[TBL] [Abstract][Full Text] [Related]
31. Mutations in
Haidar G; Clancy CJ; Shields RK; Hao B; Cheng S; Nguyen MH
Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28223379
[TBL] [Abstract][Full Text] [Related]
32. Klebsiella pneumoniae carbapenemase (KPC) in urinary infection isolates.
Bedenić B; Sardelić S; Bogdanić M; Zarfel G; Beader N; Šuto S; Krilanović M; Vraneš J
Arch Microbiol; 2021 May; 203(4):1825-1831. PubMed ID: 33507339
[TBL] [Abstract][Full Text] [Related]
33. In vitro mimicry of in vivo KPC mutations by ceftazidime-avibactam: phenotypes, mechanisms, genetic structure and kinetics of enzymatic hydrolysis.
Shen S; Tang C; Yang W; Ding L; Han R; Shi Q; Guo Y; Yin D; Hu F
Emerg Microbes Infect; 2024 Dec; 13(1):2356146. PubMed ID: 38743401
[TBL] [Abstract][Full Text] [Related]
34. Outbreak of Klebsiella pneumoniae ST11 Resistant To Ceftazidime-Avibactam Producing KPC-31 and the Novel Variant KPC-115 during COVID-19 Pandemic in Argentina.
Nicola F; Cejas D; González-Espinosa F; Relloso S; Herrera F; Bonvehí P; Smayevsky J; Figueroa-Espinosa R; Gutkind G; Radice M
Microbiol Spectr; 2022 Dec; 10(6):e0373322. PubMed ID: 36445147
[TBL] [Abstract][Full Text] [Related]
35. Evolutionary Trajectories toward Ceftazidime-Avibactam Resistance in Klebsiella pneumoniae Clinical Isolates.
Carattoli A; Arcari G; Bibbolino G; Sacco F; Tomolillo D; Di Lella FM; Trancassini M; Faino L; Venditti M; Antonelli G; Raponi G
Antimicrob Agents Chemother; 2021 Sep; 65(10):e0057421. PubMed ID: 34339281
[TBL] [Abstract][Full Text] [Related]
36. Effects of Klebsiella pneumoniae carbapenemase subtypes, extended-spectrum β-lactamases, and porin mutations on the in vitro activity of ceftazidime-avibactam against carbapenem-resistant K. pneumoniae.
Shields RK; Clancy CJ; Hao B; Chen L; Press EG; Iovine NM; Kreiswirth BN; Nguyen MH
Antimicrob Agents Chemother; 2015 Sep; 59(9):5793-7. PubMed ID: 26169413
[TBL] [Abstract][Full Text] [Related]
37. Spread and evolution of bla
Yang W; Tang C; Shen S; Shi Q; Hu F
Int J Antimicrob Agents; 2024 May; 63(5):107149. PubMed ID: 38508537
[TBL] [Abstract][Full Text] [Related]
38. In vivo selection of KPC-94 and KPC-95 in Klebsiella pneumoniae isolates from patients treated with ceftazidime/avibactam.
Guzmán-Puche J; Pérez-Nadales E; Pérez-Vázquez M; Causse M; Gracia-Ahufinger I; Mendez-Natera A; Allalou-Ruiz Y; Elías C; Oteo-Iglesias J; Torre-Cisneros J; Martínez-Martínez L
Int J Antimicrob Agents; 2022 Feb; 59(2):106524. PubMed ID: 35038557
[TBL] [Abstract][Full Text] [Related]
39. KPC-31 expressed in a ceftazidime/avibactam-resistant Klebsiella pneumoniae is associated with relevant detection issues.
Antonelli A; Giani T; Di Pilato V; Riccobono E; Perriello G; Mencacci A; Rossolini GM
J Antimicrob Chemother; 2019 Aug; 74(8):2464-2466. PubMed ID: 31318973
[No Abstract] [Full Text] [Related]
40. Activity of ceftazidime/avibactam, meropenem/vaborbactam and imipenem/relebactam against carbapenemase-negative carbapenem-resistant Enterobacterales isolates from US hospitals.
Castanheira M; Doyle TB; Deshpande LM; Mendes RE; Sader HS
Int J Antimicrob Agents; 2021 Nov; 58(5):106439. PubMed ID: 34547421
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]